Skip to main content
SpringerLink
Log in

Intensive Sequential Chemotherapy for Untreated Poor-Risk Non-Hodgkin’s Lymphoma

  • Conference paper
Book cover The Role of Multiple Intensification in Medical Oncology

Part of the book series: ESO European School of Oncology Monographs ((ESO MONOGRAPHS))

  • 35 Accesses

Abstract

First generation chemotherapy regimens like CHOP as well as second and third generation regimens — using multiple non-cross-resistant drugs and alternating cycles — have limited efficacy in high-risk non-Hodgkin’s lymphomas (NHL). Recently, the age-adjusted International Prognostic Index (IPI) established for patients less than 60 years of age with intermediate or high grade histology that the presence of 2 or 3 risk factors leads to complete remission rates and 2-year survival inferior to 55%.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Fisher RI, Gaynor ER, Dahlberg S et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 1993 328: 1002–1006

    Article  PubMed  CAS  Google Scholar 

  2. Zuckerman KS: Efficacy of intensive, high-dose anthracycline-based therapy in intermediate and high-grade non Hodgkin’s lymphomas. Sem Oncol 1994 21 Suppl 1: 59–64

    CAS  Google Scholar 

  3. Somers R, Carde P, Thomas J et al: EORTC study of non Hodgkin’s lymphoma: Phase Ill study comparing CHVmP-VB and ProMACE-MOPP in patients with stage II, Ill and IV intermediate and high grade lymphoma. Ann Oncol 1994 5 Suppl 2: 585 - S89

    Google Scholar 

  4. Vose JM, Anderson JR, Bierman PJ et al: Comparison of front line chemotherapy for aggressive non Hodgkin lymphoma using the CAP-BOP regimens. Sem Hematol 1994 31 Suppl 3: 4–8

    CAS  Google Scholar 

  5. Sertoli MR, Santini G, Chisesi T et al: MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin’s lymphoma: Results of a prospective randomized trial by the non-Hodgkin’s lymphoma cooperative study group. J Clin Oncol 1994 12: 1366–1374

    PubMed  CAS  Google Scholar 

  6. McMaster ML, Greer JP, Wolff SN et al: Results of treatment with high intensity brief duration chemotherapy in poor prognosis non-Hodgkin’s lymphoma. Cancer 1991 2: 233–241

    Article  Google Scholar 

  7. De Lena M, Ditonno P, Lorusso V et al: CEOP-B alternated with VIMB in intermediate grade and high grade non Hodgkin’s lymphoma: A pilot study. J Clin Oncol 1995 13: 953–960

    PubMed  Google Scholar 

  8. Haioun C, Lepage E, Gisselbrecht et al: Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate grade and high grade non-Hodgkin’s lymphoma in first complete remission: A study of 464 patients. J Clin Oncol 1994 12: 2543–2551

    PubMed  CAS  Google Scholar 

  9. Shipp S et al: A predictive model for aggressive non Hodgkin’s lymphoma. The International non-Hodgkin’s lymphoma prognostic factors project. N Engl J Med 1993 329: 987–997

    Article  Google Scholar 

  10. Hacq R, Sawka CA, Franssen E et al: Significance of a partial or slow response to front line chemotherapy in the management of intermediate grade or high grade non-Hodgkin’s lymphoma: A literature review. J Clin Oncol 1994 12: 1074–1084

    Google Scholar 

  11. Hrymink WM and Goodyear M: The calculation of received dose intensity. J Clin Oncol 1990 8: 1935–1937

    Google Scholar 

  12. Kwak LW, Halpern J, Olshen A et al: Prognostic significance of actual dose intensity in diffuse large cell lymphoma: Results of a tree-structured survival analysis. J Clin Oncol 8: 963–977

    PubMed  CAS  Google Scholar 

  13. Epelbaum R, Faraggi D, Ben-Arie Y et al: Survival of diffuse large cell lymphoma. Cancer 1990 66: 1124–1129

    Article  PubMed  CAS  Google Scholar 

  14. Meyer RM, Hryniuk WM, Goodyear DE: The role of dose intensity in determining outcome in intermediate grade non-Hodgkin’s lymphoma. J Clin Oncol 1991 9: 339–341

    PubMed  CAS  Google Scholar 

  15. Lepage E, Gisselbrecht C, Haioun C et al: Prognostic significance of received relative dose intensitu in non-Hodgkin’s lymphoma patients: Application to LNH-87 protocol. Ann Oncol 1993 4: 651–656

    PubMed  CAS  Google Scholar 

  16. Pettengell R, Gurney H, Radford JA et al: Granulocyte colony stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin’s lymphoma: a randomized controlled trial. Blood 1992 80: 1430–1436

    PubMed  CAS  Google Scholar 

  17. Gerhartz HH, Engelhard M, Meusers P et al: Randomized, double blind, placebo controlled phase Ill study of recombinant human granulocyte macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin’s lymphomas. Blood 1993 82: 2329–2339

    PubMed  CAS  Google Scholar 

  18. Avilés A, Diaz-Maqueo JC, Talavera A et al: Effect of granulocyte colony stimulating factor in patients with diffuse large cell lymphoma treated with intensive chemotherapy. Leukemia and Lymphoma 1994 15: 153–157

    Article  PubMed  Google Scholar 

  19. Engelhard M, Gerhartz H, Brittinger G et al: Cytokine efficiency in the treatment of high-grade malignant non-Hodgkin’s lymphomas: Results of a randomized double blind placebo controlled study with intensified COP-BLAM ± rhGM-CSF. Ann Oncol 1994 5 Suppl 1: S213

    Google Scholar 

  20. Grigg A, Wolf M, Levi J et al: Escalated dose epirubicin cyclophosphamide with fiigrastim for patients with aggressive non-Hodgkin’s lymphoma. Proc ASCO 1995 12 1255: 411

    Google Scholar 

  21. Shambaugh S, Belman N, Ehmann WC et al: Dose-intensified chemotherapy for intermediate grade non-Hodgkin lymphoma. Proc ASCO 1995 12 1296a: 421

    Google Scholar 

  22. Casanova L, Gomez H, Kahatt C et al: Biweekly intensified CHOP (I-CHOP) regimen using GM-CSF 5MOLGRAMOSTIM) in aggressive non Hodgkin’s lymphoma. Proc ASCO 1995 12 1303a: 423

    Google Scholar 

  23. Gordon LI, Andersen J, Habermann TM et al: Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: determination of the maximum tolerated dose of ProMACE-CytaBOM. J Clin Oncol 1996 14: 1275–1281

    PubMed  CAS  Google Scholar 

  24. Shipp MA, Neuberg D, Janicek M et al: High dose CHOP as initial therapy for patients with poor prognosis aggressive non-Hodgkin’s lymphoma: a dose-finding pilot study. J Clin Oncol 1995 13: 2916 2923

    Google Scholar 

  25. Philip T, CGuglielmi C, Hagenbeek A et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy sensitive non-Hodgkin’s lymphoma. N Engl J Med 1995 333: 1540–1545

    Article  PubMed  CAS  Google Scholar 

  26. Haioun C, Lepage E, Gisselbrecht E et al: Autologous bone marrow transplantation versus sequential chemotherapy for aggressive non-Hodgkin’s lymphoma partially responding to first line chemotherapy: A study of 96 patients enrolled in the LNH87 protocol. Blood 1995 86 Suppl 1: a823

    Google Scholar 

  27. Gherlinzoni F, Martelli M, Mazza P et al: Autologous bone marrow transplantation versus DHAP in aggressive non-Hodgkin’s lymphomas partially responding to first line chemotherapy. Blood 1994 84: a234 (abstr 922)

    Google Scholar 

  28. Verdonck LF, Van Putten WLJ, Hagenbeek A et al: Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin’s lymphoma. N Engl J Med 1995 332: 1045–1051

    Article  PubMed  CAS  Google Scholar 

  29. Sweetenham JW, Proctor SJ, Blaise D et al: High dose therapy and autologous bone marrow transplantation in first complete remission for adult patients with high-grade non-Hodgkin’s lymphoma: The EBMT experience. Ann Oncol 1994 5 Suppl 2: S155 - S159

    Article  Google Scholar 

  30. Vitolo U, Cortellazzo S, Liberati AM et al: Intensified chemotherapy followed by myeloablative therapy and autologous stem cell transplantation as first line therapy in high risk diffuse large cell lymphoma. Blood 1995 86 Suppl 1 a1819: 458

    Google Scholar 

  31. Haioun C, Lepage E, Gisselbrecht C et al: Autologous bone marrow transplantation versus sequential chemotherapy for aggressive non-Hodgkin’s lymphoma in first complete remission: A study of 542 patients (LNH-87 protocol). Blood 1995 86 Suppl 1: a1816

    Google Scholar 

  32. Milpied N, Lamy T, Gaillard F et al: Intensive short term therapy for adults with disseminated intermediate or high grade non Hodgkin’s lymphomas: Analysis of prognostic factors in a prospective multicenter trial. BMT 1990 17 Suppl 1: S30

    Google Scholar 

  33. Gianni AM, Bregni M, Siena S et al: Five-year update of the Milan Cancer Institute randomized trial of high-dose sequential versus MACOP-B therapy for diffuse large-cell lymphomas. Proc Annual Meeting ASCO 1994 13:Al263

    Google Scholar 

  34. Schmitz N, Linch DC, Dreger P et al: Randomised trial of filgrastim mobilised peripheral blood progenitor cell transplantation versus autologous bone marrow transplantation in lymphoma patients. The Lancet 1996 347: 353–357

    Article  CAS  Google Scholar 

  35. Gribben JG, Freedmon AS, Neuberg D et al: Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991 325: 1525–1533

    Article  PubMed  CAS  Google Scholar 

  36. Sharp JG, Kessinger A, Mann S et al: Outcome of high-dose therapy and autologous transplantation in non-Hodgkin’s lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest. J Clin Oncol 1996 14: 214–219

    PubMed  CAS  Google Scholar 

  37. Milligan DW, Kolb HJ, Pearce R et al: MDS after autografting for lymphoma: A retrospective analysis of the EBMT registry. BMT 1996 17 Suppl 1: a634

    Google Scholar 

  38. Shea TC, Mason JR, Storniolo AM et al: Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte macrophage colony stimulating factor and repeated infusions of autologous peripheral blood progenitor cells: A novel and effective method for delivering multiple courses of dose intensive therapy. J Clin Oncol 1992 10: 464–473

    PubMed  CAS  Google Scholar 

  39. Tepler I, Cannistra SA, Frei E et al: Use of peripheral blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy. J Clin Oncol 1993 11: 1583–1591

    PubMed  CAS  Google Scholar 

  40. Fennelly D, Wasserheit C, Schneider J et al: Simultaneous dose escalating and schedule intensification of carboplatin based chemotherapy using peripheral blood progenitor cells and filgrastim: A phase I trial. Cancer Res 1994 54: 6137–6142

    PubMed  CAS  Google Scholar 

  41. Pettengell R, Woll PJ, Tatcher N et al: Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of hematopoietic progenitors in whole blood. J Clin Oncol 1995 13: 148–156

    PubMed  CAS  Google Scholar 

  42. Wheeler C, Shulman LN, Elias A et al: Sequential ifosfamide, carboplatin and etoposide with steroids and cyclophosphamide (Cy/AG-CSF) mobilized peripheral blood progenitor cell (PBPC) support (SPICE) in relapsed lymphomas. Proc Am Soc Clin Oncol 1995 14: 913A

    Google Scholar 

  43. Faucher C, Le Corroller AG, Blaise D et al: Comparison of G-CSF primed peripheral blood progenitor cells and bone marrow autotransplantation: Clinical assessment and cost-effectiveness. BMT 1994 14: 895–901

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut Paoli-Calmettes, 232 Boulevard Sainte Marguerite, 13273, Marseille, France

    A. M. Stoppa, R. Bouabdallah, N. Vey, R. Costello, J. Camerlo, G. Novakovitch, C. Chabannon, V. J. Bardou, D. Blaise, J. A. Gastaut & D. Maraninchi

  2. Centre Hospitalier Regional Lapeyronie, 371 Avenue Doyen Giraud, 34295, Montpellier, France

    J. F. Rossi

Authors
  1. A. M. Stoppa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Bouabdallah
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N. Vey
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. F. Rossi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. Costello
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. Camerlo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G. Novakovitch
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C. Chabannon
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. V. J. Bardou
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. D. Blaise
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. J. A. Gastaut
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. D. Maraninchi
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institut Multidisciplinaire d’Oncologie, 1272, Genolier, Switzerland

    M. S. Aapro

  2. European Institute of Oncology, Via Ripamonti 435, 20141, Milano, Italy

    M. S. Aapro

  3. Insitut Paoli Calmettes, 232 Bd. de Sainte Marguerite, 13273, Marseille Cedex 9, France

    D. Maraninchi

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Stoppa, A.M. et al. (1998). Intensive Sequential Chemotherapy for Untreated Poor-Risk Non-Hodgkin’s Lymphoma. In: Aapro, M.S., Maraninchi, D. (eds) The Role of Multiple Intensification in Medical Oncology. ESO European School of Oncology Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-01156-0_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-01156-0_5

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-01158-4

  • Online ISBN: 978-3-662-01156-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation